Highest-materiality recent filing
Nexalin adopts amended bylaws lowering quorum to 1/3, adding forum selection clause
Quorum for stockholder meetings reduced from majority to one-third of outstanding voting power.
Nexalin acquires PONM digital health platform for HALO Clarity for $1.3M in stock
Acquisition of all PONM shares for $1.3M in Nexalin common stock; first tranche of 959,016 shares issued at closing.
Entered contract with Lindus Health for pivotal study; direct fees ~$944,820 plus pass-through expenses.
Nexalin announces pivotal HALO Clarity trial for insomnia to support FDA de novo submission
150-patient, triple-blinded, sham-controlled randomized study via decentralized NeuroCare virtual clinic with Lindus Health.
Nexalin receives Nasdaq deficiency notice for non-compliance with $1 minimum bid price rule
Received deficiency letter from Nasdaq on Jan 21, 2026 due to bid price below $1.00 for 30 consecutive business days.
Nexalin releases December 2025 investor presentation; cash $4.4M, no debt, warrants expired
Financial snapshot: Cash $4.4M, zero debt, 18.2M common shares, 22.3M fully diluted; warrants expired Sept 2025.
Nexalin Technology increases ATM offering capacity to $10M from $3.1M
Amendment No. 2 to equity distribution agreement with Maxim Group LLC executed Oct 15, 2025.
Nexalin Technology warrants expired on Sep 22, 2025; delisted from Nasdaq
Warrants with $4.15 exercise price expired at 5 PM ET on September 22, 2025.
Nexalin Appoints Justin Van Fleet as CFO Effective August 1, 2025
Justin Van Fleet, CPA, appointed CFO, effective August 1, 2025; previously partner at Marcum LLP.
Nexalin appoints Justin Van Fleet as CFO effective August 1, 2025
Justin Van Fleet, former partner at Marcum LLP, named CFO; base salary $250,000.
Nexalin stockholders elect all directors, approve equity plan amendment and auditor ratification
All five director nominees elected; for votes ranged from 6,259,490 to 6,375,246, zero against.
Nexalin closes partial over-allotment exercise, raising $312K at $1.30/share
On June 5, 2025, Maxim Group partially exercised its over-allotment option for 240,000 shares.
Nexalin Technology prices $5.0M public offering of 3.85M shares at $1.30/share
Offering of 3,850,000 shares at $1.30 per share for gross proceeds of ~$5.0M.
Nexalin reduces ATM offering size from ~$9.8M to $3.1M
On May 5, 2025, Nexalin amended equity distribution agreement with Maxim Group, cutting max aggregate offering price from $9,777,825 to $3,100,000.
Marcum resigned April 16, 2025; company engaged CBIZ CPAs P.C., which acquired Marcum's attest business.
SEC declares Nexalin S-1 effective covering up to 2.8M shares from warrant exercises
Registration statement effective for up to 2,798,613 shares of common stock.
Nexalin regains compliance with Nasdaq minimum bid price rule
Received notice from Nasdaq on Oct. 31, 2024, confirming compliance with Rule 5550(a)(2).
Nexalin Technology receives Nasdaq delisting notice for bid price below $1.00
Received Nasdaq notice on Sep 23, 2024 due to bid price below $1.00 for 30 consecutive business days.
Nexalin appoints Carolyn Shelton as SVP Quality, Regulatory & Clinical Affairs
Carolyn Shelton appointed SVP Quality, Regulatory and Clinical Affairs effective Sept 16, 2024.
All five director nominees elected: Leslie Bernhard, Mark White, David Owens, Alan Kazden, Ben V. Hu.
SVP of Clinical, Quality, & Regulatory Affairs Michael Nketiah resigns effective Aug 16, 2024
Michael Nketiah resigned as SVP of Clinical, Quality, & Regulatory Affairs, effective August 16, 2024.
Nexalin raises $5.25M in public offering to regain Nasdaq equity compliance
Received Nasdaq notice on May 16, 2024 for stockholders' equity of $2.327M, below $2.5M minimum.
Nexalin closes $5.25M public offering of 3M shares at $1.75 per share
Closed public offering of 3,000,000 common shares at $1.75/share; gross proceeds approximately $5,250,000.
Nexalin Technology prices 3M-share public offering at $1.75, gross proceeds ~$5.25M
Offering of 3,000,000 shares of common stock at $1.75 per share; gross proceeds ~$5.25 million.
Nexalin Gen-2 neurostimulation device approved by Brazilian regulator Anvisa
Anvisa approved Nexalin's Gen-2 15 mA neurostimulation device for sale in Brazil.
Nexalin receives Nasdaq delisting notice for stockholders' equity deficiency
Nasdaq notified Nexalin on May 16, 2024 of non-compliance with minimum $2.5M equity requirement.
Nexalin regains Nasdaq minimum bid price compliance
Received notice from Nasdaq on April 23, 2024, of compliance with Rule 5550(a)(2).
Nexalin CEO details clinical progress, Gen-3 HALO headset, and government market expansion
Positive clinical results from UCSD study: Gen-2 tACS reduced post-concussive and PTSD symptoms in veterans with mTBI.
Nexalin shareholders approve reverse stock split amendment with board discretion on ratio
Special meeting held March 7, 2024; 4,587,248 shares present (61.7% of outstanding).
Nexalin receives Nasdaq delisting notice; bid price and equity rules non-compliant
Nasdaq notified Nexalin on May 10, 2023 of bid price deficiency; 180-day cure period expired Nov 6, 2023 without compliance.
Nexalin CFO Marilyn Elson resigns, effective Nov 1, 2023; to remain as Controller
CFO Marilyn Elson submitted resignation on September 21, 2023, effective November 1, 2023.
Nexalin forms JV with Wider Come to commercialize tACS devices in Asia; Wider funds ops and 4 trials
JV ownership: Wider 52%, Nexalin 48%; will market Gen-2 tACS devices in China and Asia Pacific.
Nexalin Technology receives Nasdaq bid price deficiency notice; has 180 days to regain compliance
Nasdaq notified Nexalin on May 10, 2023 that its common stock closing bid price fell below $1.00 for 30 consecutive business days.
On September 16, 2024, Nexalin Technology, Inc. (“Nexalin”) appointed Carolyn Shelton as Senior Vice President Quality, Regulatory and Clinical Affairs, effective as of September 16, 2024.
On July 29, 2024, Michael Nketiah submitted his resignation as the Senior Vice President of Clinical, Quality, & Regulatory Affairs of Nexalin Technology Inc. (the "Company").
On September 21, 2023, Marilyn Elson submitted her resignation as the Chief Financial Officer of Nexalin Technology Inc. (the “Company”).
Max materiality 0.80 · Median 0.60 · Most common event other_material